Kardi Trading Private Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Kardi Trading Private Limited Pharmaceutical Export Portfolio Dataset — 9 Products, $9.2M FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Kardi Trading Private Limited — Pharmaceutical Exporter Profile (2026) | 9 Products, $9.2M Trade | TransData Nexus

Kardi Trading Private Limited

Indian Pharmaceutical Exporter · Oncology Specialist · $9.2M Total Trade · DGFT Verified

Kardi Trading Private Limited is an Indian pharmaceutical exporter with a total trade value of $9.2M across 9 products in 5 therapeutic categories. Based on 363 verified export shipments from Indian Customs (DGFT) records, Kardi Trading Private Limited is the #1 Indian exporter in 2 products including Semaglutide, Regorafenib. Top exports include Carboplatin ($2.6M), Paclitaxel ($2.4M), Protein ($2.1M).

Kardi Trading Private Limited — Export Portfolio & Destination Treemap

Kardi Trading Private Limited pharmaceutical export portfolio — 9 products across 5 therapeutic categories. Source: Indian Customs (DGFT).

Who is Kardi Trading Private Limited? — Company Overview & Market Position

Kardi Trading Private Limited is a privately held pharmaceutical export company based in Hyderabad, Telangana, India. Established on December 10, 2018, the company operates under the Corporate Identification Number (CIN) U51909TG2018PTC128909. The registered office is located at H.No.8-3-940 & 940/A to E, Tirumala Shah Residency, Yellareddyguda Ameerpet, Hyderabad, Telangana, 500073. Kardi Trading specializes in the wholesale trading of pharmaceutical formulations, including tablets, capsules, syrups, and injections.

The company has demonstrated significant growth in recent years. In the financial year ending March 31, 2024, Kardi Trading reported a 31.98% increase in total revenue compared to the previous year. Profitability also improved, with a 64.1% increase in profit. The net worth of the company saw a substantial rise of 103.38% during the same period. As of the latest available data, the authorized capital stands at ₹1.00 million, with a paid-up capital of ₹0.10 million.

What Does Kardi Trading Private Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Carboplatin$2.6M 2

Product Portfolio — Top 9 by Export Value

Kardi Trading Private Limited exports 9 pharmaceutical products across 5 therapeutic categories. Market leader (#1 exporter) in 2 products.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Carboplatin	Oncology	$2.6M	130	3.7%	7
2	Paclitaxel	Oncology	$2.4M	83	2.9%	9
3	Protein	Nutritional Supplements	$2.1M	58	14.0%	2
4	Semaglutide	Advanced Diabetes Medications	$1.2M	41	24.3%	1
5	Sofosbuvir	Antiviral & HIV Medications	$311.7K	17	0.8%	6
6	Velpatasvir	Antiviral & HIV Medications	$311.7K	17	1.3%	5
7	Regorafenib	Advanced Oncology	$116.0K	8	11.5%	1
8	Lenvatinib	Advanced Oncology	$65.1K	6	3.1%	6
9	Pazopanib	Advanced Oncology	$50.8K	3	0.6%	7

Kardi Trading Private Limited exports 9 pharmaceutical products across 5 therapeutic categories with a total export value of $9.2M. The company is the #1 Indian exporter in 2 products: Semaglutide, Regorafenib. The top category is Oncology (55.1% of portfolio), followed by Nutritional Supplements (22.5%), indicating a concentrated portfolio with the top 5 products accounting for 94.1% of total export value.

Kardi Trading Private Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Kardi Trading Private Limited operates its manufacturing facilities in Hyderabad, Telangana, India. The company specializes in the production of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. Specific details regarding the manufacturing plant locations, capacities, and specializations are not publicly disclosed. However, the company's significant export activities and product portfolio suggest a well-established manufacturing infrastructure capable of meeting international standards.

3Key Leadership

The leadership team of Kardi Trading Private Limited comprises two directors:

Sai Vishwajeet Shaw: Serving as a director since the company's inception on December 10, 2018.

Ramchandraiah Metthati: Also appointed as a director on December 10, 2018.

Both directors have been associated with the company for over seven years, indicating a stable leadership structure. Additional details regarding other key executives are not publicly available.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Kardi Trading Private Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Kardi Trading Private Limited's export activities are primarily focused on finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. The company's trade data indicates a significant presence in various international markets, with a total export value of $9.2 million USD across 363 shipments. The top five exported products include:

Semaglutide: $1.2 million USD, accounting for 24.3% of the market share.

Protein: $2.1 million USD, with a 14.0% market share.

Carboplatin: $2.6 million USD, representing 3.7% of the market share.

Paclitaxel: $2.4 million USD, holding a 2.9% market share.

Sofosbuvir: $312,000 USD, comprising 0.8% of the market share.

The therapeutic categories with the highest export values are:

Kardi Trading Private Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Specific details regarding Kardi Trading Private Limited's FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, and inspection history are not publicly available. However, the company's substantial export activities and focus on finished pharmaceutical formulations suggest compliance with international regulatory standards, including those set by the FDA. The emphasis on high-demand products like Semaglutide and Protein indicates adherence to stringent quality and regulatory requirements.

2WHO & EU GMP

While specific certifications such as WHO prequalification and EU GMP certificates are not publicly disclosed, Kardi Trading's significant export activities and focus on finished pharmaceutical formulations imply adherence to international quality standards. The company's product portfolio, including oncology and advanced diabetes medications, suggests compliance with Good Manufacturing Practices (GMP) recognized by global regulatory bodies.

3CDSCO & Indian Regulatory

Kardi Trading Private Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

Kardi Trading Private Limited operates in a competitive pharmaceutical export market, with several key players in overlapping therapeutic categories. The company's top five products—Semaglutide, Protein, Carboplatin, Paclitaxel, and Sofosbuvir—are in high-demand therapeutic areas, indicating a competitive positioning. While specific market share comparisons and head-to-head analyses are not publicly available, Kardi Trading's focus on high-demand products and diverse therapeutic categories suggests a strategic approach to capturing market share.

2Key Differentiators

Kardi Trading's key differentiators include a focused product portfolio with high-demand products like Semaglutide and Protein, a diversified presence across multiple therapeutic categories, and a significant export footprint in emerging markets. The company's emphasis on finished pharmaceutical formulations indicates a commitment to quality and compliance with international regulatory standards.

3Strategic Position

Kardi Trading Private Limited's current strategic direction appears to be centered on exporting high-demand finished pharmaceutical formulations across diverse therapeutic categories. The company's significant presence in oncology, nutritional supplements, and advanced diabetes medications aligns with global health trends, positioning Kardi Trading favorably in these markets. The focus on emerging markets suggests a strategy to leverage growth opportunities in regions with increasing healthcare needs.

Buyer Due Diligence Brief — Evaluating Kardi Trading Private Limited as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Kardi Trading Private Limited has demonstrated a strong track record in pharmaceutical exports, with a total export value of $9.2 million USD across 363 shipments. The company's focus on finished pharmaceutical formulations indicates a commitment to quality and compliance with international standards. The substantial presence in oncology, nutritional supplements, and advanced diabetes medications suggests reliability in meeting market demands.

2Certifications to Verify

Importers should verify the following certifications to ensure product quality and regulatory compliance:

FDA Approval: Confirm that the products are approved by the U.S. Food and Drug Administration. Verification can be done through the FDA's official website or by contacting the manufacturer directly.

WHO-GMP Certification: Ensure that the manufacturing facilities comply with World Health Organization's Good Manufacturing Practices. This can be verified by checking the WHO's official prequalification list.

Frequently Asked Questions — Kardi Trading Private Limited

How many pharmaceutical products does Kardi Trading Private Limited export from India?

Kardi Trading Private Limited exports 9 pharmaceutical products across 5 therapeutic categories. The top exports are Carboplatin ($2.6M), Paclitaxel ($2.4M), Protein ($2.1M), Semaglutide ($1.2M), Sofosbuvir ($311.7K). Total export value is $9.2M.

What is Kardi Trading Private Limited's total pharmaceutical export value?

Kardi Trading Private Limited's total pharmaceutical export value is $9.2M, based on 363 verified shipments recorded in Indian Customs (DGFT) data.

In which products is Kardi Trading Private Limited the #1 Indian exporter?

Kardi Trading Private Limited is the #1 Indian exporter in 2 products: Semaglutide (24.3% market share), Regorafenib (11.5% market share).

What therapeutic categories does Kardi Trading Private Limited cover?

Kardi Trading Private Limited exports across 5 therapeutic categories. The largest are Oncology (55.1%, 2 products), Nutritional Supplements (22.5%, 1 products), Advanced Diabetes Medications (13.1%, 1 products).

Get Full Kardi Trading Private Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.